首页> 美国卫生研究院文献>Filaria Journal >Multi-center screening of the Pathogen Box collection for schistosomiasis drug discovery
【2h】

Multi-center screening of the Pathogen Box collection for schistosomiasis drug discovery

机译:多中心筛查血吸虫病药物的病原盒收集

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroundOver the past five years, as a public service to encourage and accelerate drug discovery for diseases of poverty, the Medicines for Malaria Venture (MMV) has released box sets of 400 compounds named the Malaria, Pathogen and Stasis Boxes. Here, we screened the Pathogen Box against the post-infective larvae (schistosomula) of Schistosoma mansoni using assays particular to the three contributing institutions, namely, the University of California San Diego (UCSD) in the USA, the Swiss Tropical and Public Health Institute (Swiss TPH) in Switzerland, and the Fundação Oswaldo Cruz (FIOCRUZ) in Brazil. With the same set of compounds, the goal was to determine the degree of inter-assay variability and identify a core set of active compounds common to all three assays. New drugs for schistosomiasis would be welcome given that current treatment and control strategies rely on chemotherapy with just one drug, praziquantel.
机译:背景技术在过去的五年中,作为鼓励和加速贫困疾病药物研发的公共服务,疟疾药物风险管理公司(MMV)已发布了盒装的400套化合物,分别名为“疟疾,病原体和静息盒”。在这里,我们使用三个贡献机构特有的检测方法,针对曼氏血吸虫的感染后幼虫(血吸虫)筛选了病原体盒,这三个检测机构分别是美国加利福尼亚大学圣地亚哥分校(UCSD),瑞士热带和公共卫生研究所(瑞士TPH)和巴西的FundaçãoOswaldo Cruz(FIOCRUZ)。对于同一组化合物,目标是确定测定间差异的程度,并确定这三种测定共有的一组活性化合物的核心。鉴于目前的治疗和控制策略都依赖于仅用一种药物吡喹酮进行的化疗,因此,用于血吸虫病的新药物将受到欢迎。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号